Scott Ribich

Scott Ribich

Company: Accent Therapeutics

Job title: Vice President, Biology


Scott Ribich is Vice President of Biology, overseeing all aspects of discovery biology at Accent Therapeutics. Prior to joining Accent, Scott was Director of Biology at Epizyme, where he was responsible for leading teams involved with target identification, drug discovery and clinical candidate support. He started his career in drug discovery at GlaxoSmithKline and Sirtris Pharmaceuticals, where he worked on multiple early stage and clinical stage assets. Scott holds a B.S. in biology from Massachusetts Institute of Technology, a Ph.D. in biochemistry from Harvard University and completed his postdoctoral training at Harvard Medical School and Brigham and Women’s Hospital.


ADAR1 as a Therapeutic Target in Type I Interferon Signaling-High Cancer 2:20 pm

• A subset of cancer cell lines and tumors displays endogenous elevated Type I IFN signaling • ADAR1 loss induces selective cell killing in these cells through elevated dsRNA signaling by MDA5 (with downstream IFN production) and PKR (and downstream inhibition of translation) • These studies indicate an ADAR1 inhibitor would be a useful therapeutic…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.